The U.S. Patent & Trademark Office (PTO) granted Argentum Pharmaceuticals LLC’s petition for inter partes review (IPR) against all patent claims in the first patent listed in the Food & Drug Administration’s Orange Book as covering Valeant Pharmaceuticals’ JUBLIA® (efinaconazole topical solution 10%). Argentum is challenging all claims of U.S. Patent No. 7,214,506 (‘506 patent).
In granting Argentum’s petition, the PTO concluded that Argentum “has established a reasonable likelihood that it would prevail in showing the unpatentability of each of the challenged claims of the ‘506 patent.” The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO’s Patent Trial & Appeal Board. A final decision on patentability in the IPR is due by May 1, 2018.
About Argentum Pharmaceuticals
Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices. http://www.argentumpharmaceuticals.com